A monomer represented by Chemical Formula 1: ##STR00001##
wherein, in Chemical Formula 1, R.sup.1, R.sup.2, A.sup.1, A.sup.2, L.sup.1, L.sup.2, o, p, q, and r are the same as defined in the detailed description.

A monomer represented by Chemical Formula 1:

##STR00001##

wherein, in Chemical Formula 1, R.sup.1, R.sup.2, A.sup.1, A.sup.2, L.sup.1, L.sup.2, o, p, q, and r are the same as defined in the detailed description.

A monomer represented by Chemical Formula 1:

##STR00001##

wherein, in Chemical Formula 1, R.sup.1, R.sup.2, A.sup.1, A.sup.2, L.sup.1, L.sup.2, o, p, q, and r are the same as defined in the detailed description.

A compound of the formula, plus devices incorporating this compound, and a method of marking such devices:

##STR00001## wherein: A represents a phenyl group, a naphthyl group, a biphenyl group or two phenyl groups linked by a C.sub.1-C.sub.8 alkyl chain; B.sup.1 and B.sup.2 in each occurrence are independently selected side chains of the structure

(Y.sup.1).sub.n-L-(Y.sup.2).sub.mX wherein: Y.sup.1 and Y.sup.2 in each occurrence are independently selected from O, CO.sub.2 and CH.sub.2O, m and n in each occurrence are independently selected from 0 or 1; L in each occurrence is a C.sub.2-C.sub.14 straight chain alkyl group; and X in each occurrence is an independently selected cross linkable group; C is a side chain of the structure (Z.sup.1).sub.p-M-(Z.sup.2).sub.q-E wherein: Z.sup.1 and Z.sup.2 are independently selected from O, CO.sub.2 and CH.sub.2O, p and q in each occurrence are independently selected from 0 or 1; M is a C.sub.1-C.sub.14 straight chain alkyl group; and E comprises a charge transport group; D is a side chain of the structure (W.sup.1).sub.rN(W.sup.2).sub.sF wherein: W.sup.1 and W.sup.2 are independently selected from O, CO.sub.2 and CH.sub.2O, r and s in each occurrence are independently selected from 0 or 1; N is a C.sub.1-C.sub.14 straight chain alkyl group; and F comprises a charge transport group or light emitter group; and wherein the charge transport group E does not contain a fluorene group other than those that form part of a spirobifluorenearylamine motif.

In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions.

In one aspect, the present disclosure provides methods of preparing a primary or secondary amine and hydroxylated aromatic compounds. In some embodiments, the aromatic compound may be unsubstituted, substituted, or contain one or more heteroatoms within the rings of the aromatic compound. The methods described herein may be carried out without the need for transition metal catalysts or harsh reaction conditions.

Provided are a compound capable of degrading a target protein using ubiquitin and having a targeted protein binding moiety (TBM) structure binding to a target protein or polypeptide and a ubiquitin binding moiety (UBM) structure to which ubiquitin is bound, wherein the compound can be induced to polyubiquitination by the UBM structure present in the compound, and thus have an advantage of becoming a protein degrader capable of degrading a target protein or polypeptide.

Provided are a compound capable of degrading a target protein using ubiquitin and having a targeted protein binding moiety (TBM) structure binding to a target protein or polypeptide and a ubiquitin binding moiety (UBM) structure to which ubiquitin is bound, wherein the compound can be induced to polyubiquitination by the UBM structure present in the compound, and thus have an advantage of becoming a protein degrader capable of degrading a target protein or polypeptide.

The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.

The present technology provides compounds selective for the Grp94 isoform, as well as compositions including such compounds, that are useful for treatment of multiple myeloma, melanoma, lung cancer, hepatocellular carcinoma, breast cancer, prostate cancer, and/or glaucoma. Methods using the compound are also provided.